Item 7.01 Regulation FD Disclosure.

On May 17, 2022, VYNE Therapeutics Inc. (the "Company") hosted a virtual Key Opinion Leader ("KOL") event on the Company's InhiBET™ BET inhibitor platform. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The presentation will also be available online at https://vynetherapeutics.com/investors-media/events_presentations/ as of May 17, 2022; however, the Company's website and any information contained on the website are not incorporated herein.

The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is being filed herewith.

Exhibit No.               Description

  99.1                      KOL Event Presentation, dated May 17, 2022.

                          Cover Page Interactive Data File (embedded within the
104                       Inline XBRL document)

© Edgar Online, source Glimpses